AGIO
Agios Pharmaceuticals, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website agios.com
- Employees(FY) 389
- ISIN US00847X1046
Performance
-7.46%
1W
+20.04%
1M
+20.12%
3M
+59.06%
6M
+145.26%
YTD
+154.05%
1Y
Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Technical Analysis of AGIO 2024-11-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-07 06:57
- 2024-11-05 09:05
- 2024-11-04 20:05
- 2024-11-01 10:47
- 2024-11-01 09:40
- 2024-11-01 08:57
- 2024-11-01 03:03
- 2024-10-31 10:34
Agios Pharmaceuticals Shares Fall After Q3 Revenue Miss(MT Newswires)
- 2024-10-31 06:42
Agios Pharmaceuticals: Q3 Earnings Snapshot(Associated Press Finance)
- 2024-10-31 06:30
- 2024-10-30 19:45
- 2024-10-30 18:30
- 2024-10-23 07:00
- 2024-10-22 19:00
- 2024-10-17 07:00
- 2024-10-16 19:00
- 2024-10-16 08:03
- 2024-09-27 11:29
- 2024-09-27 10:34
- 2024-09-27 07:28
- 2024-09-26 16:05
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.(Investor's Business Daily)
- 2024-09-17 07:56
- 2024-09-14 08:28
- 2024-09-12 11:33
- 2024-09-12 06:33
Agios Pharmaceuticals’ tebapivat gains FDA orphan drug designation(Pharmaceutical Technology)
- 2024-09-11 07:36
- 2024-09-11 07:00
- 2024-09-10 19:00
- 2024-09-06 11:31
- 2024-09-05 07:00
Page 1 of 9
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.